Metabolic Biomarker Testing Market Report 2026

The metabolic biomarker testing market size has grown strongly in recent years. It will grow from $3.06 billion in 2025 to $3.32 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to advancements in analytical chemistry techniques, growth in chronic and metabolic disorders, increased use of laboratory diagnostics, expansion of clinical research activities, availability of high-throughput testing platforms.

The metabolic biomarker testing market size is expected to see strong growth in the next few years. It will grow to $4.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for personalized healthcare solutions, rising investments in precision diagnostics, expansion of preventive health screening programs, growing use of ai-driven data interpretation, increasing collaboration between diagnostics and pharmaceutical companies. Major trends in the forecast period include increasing adoption of metabolomics-based diagnostics, rising use of biomarkers in personalized medicine, growing integration of advanced analytical techniques, expansion of early disease detection applications, enhanced focus on data-driven clinical decision making.

The increasing prevalence of diabetes is expected to drive the growth of the metabolic biomarker testing market in the coming years. Diabetes is a chronic condition characterized by elevated blood glucose levels due to the body’s inability to produce or effectively utilize insulin. The increase in diabetes cases is fueled by unhealthy diets, particularly high intake of processed foods and sugary beverages, and sedentary lifestyles with limited physical activity. Additionally, an aging population and a family history of diabetes raise the risk, reflecting a genetic predisposition. Metabolic biomarker testing plays a key role in diagnosing, monitoring, and managing metabolic disorders such as diabetes by offering insights into metabolic processes and abnormalities at the molecular level. For example, in April 2025, the International Diabetes Federation (IDF), a Belgium-based diabetes advocacy organization, reported that the number of adults (aged 20-79 years) living with diabetes worldwide reached 589 million, marking a significant increase from previous years. The total number of adults with diabetes is projected to reach 853 million by 2050. Consequently, the growing prevalence of diabetes is expected to propel the expansion of the metabolic biomarker testing market.

Major companies in the metabolic biomarker testing market are concentrating on developing innovative solutions, such as lab-quality home blood testing platforms, to address the growing demand for convenient, accurate, and timely metabolic health monitoring. Lab-quality home blood testing platforms are compact, user-friendly devices intended for at-home use that deliver results comparable to conventional laboratory tests. For example, in January 2023, SiPhox Health, Inc., a U.S.-based health technology company, introduced the world's first lab-quality home blood testing platform, enabling users to monitor multiple metabolic biomarkers from the comfort of their homes. The platform utilizes proprietary technology to ensure high accuracy, provides real-time results via a connected app, and supports a broad range of metabolic health assessments, including glucose, lipid profiles, and other essential indicators. Its distinctive combination of lab-grade precision and at-home accessibility allows for more frequent monitoring, early detection of metabolic disorders, and personalized health management.

In June 2024, Lifesum AB, a Sweden-based healthy eating and wellness platform provider, acquired Lykon GmbH for an undisclosed sum. The acquisition is intended to integrate Lykon's biomarker testing into Lifesum's platform to deliver personalized health insights, expand wellness services, and reinforce Lifesum's presence in the advanced wellness market. Lykon GmbH is a Germany-based company specializing in personalized metabolic and nutritional testing.

Major companies operating in the metabolic biomarker testing market are Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., PerkinElmer Inc., bioMérieux S.A., LECO Corporation, Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, SCIEX, Promega Corporation, Cayman Chemical Company, Metabolon Inc., Biocrates Life Sciences AG, Human Metabolome Technologies Inc., KineMed Inc., Evosep Biosystems A/S, Creative Proteomics Inc., Lipotype GmbH, Metabolomic Diagnostics Ltd, Stemina Biomarker Discovery Inc., Chenomx Inc., GlycoPath Pty Ltd.

North America was the largest region in the metabolic biomarker testing market in 2025. The regions covered in the metabolic biomarker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metabolic biomarker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the metabolic biomarker testing market by increasing costs of imported analytical instruments, reagents, assay kits, and high-precision detection equipment. Clinical laboratories and research institutions in North America and Europe are most affected due to reliance on imported mass spectrometry and chromatography systems, while Asia-Pacific faces pricing pressure on instrument exports. These tariffs are raising testing costs and slowing laboratory upgrades. However, they are also encouraging domestic manufacturing of diagnostic instruments, local reagent production, and regional innovation in cost-efficient testing solutions.

The metabolic biomarker testing market research report is one of a series of new reports that provides metabolic biomarker testing market statistics, including metabolic biomarker testing industry global market size, regional shares, competitors with a metabolic biomarker testing market share, detailed metabolic biomarker testing market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic biomarker testing industry. This metabolic biomarker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Metabolic biomarker testing involves analyzing specific molecules in biological samples, such as blood or urine, to evaluate metabolic processes and detect imbalances or dysfunctions. This type of testing is useful for diagnosing metabolic disorders, monitoring health conditions, and informing personalized treatment approaches.

The primary categories of metabolic biomarker testing include separation techniques, detection techniques, and others. Separation techniques employ physical or chemical methods to isolate particular metabolites from a biological sample based on properties like size, charge, or affinity, aiding in the purification and identification of metabolic biomarkers and providing high accuracy in detecting metabolites. The types of indications cover cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others, while applications span drug assessment, nutrigenomics, toxicology testing, personalized medicine, functional genomics, and more. The end users comprise pharmaceutical and biotech companies, diagnostic tool manufacturers, healthcare information technology (IT) providers, and clinical laboratories.

The metabolic biomarker testing market consists of revenues earned by entities by providing services such as laboratory testing, analysis of blood, urine, and other biological samples, and personalized health assessments. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic biomarker testing market also includes sales of diagnostic kits, assay reagents, and testing equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.